Your browser is no longer supported. Please, upgrade your browser.
FPRX Five Prime Therapeutics, Inc. daily Stock Chart
Five Prime Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.97 Insider Own0.30% Shs Outstand35.43M Perf Week-11.11%
Market Cap175.24M Forward P/E- EPS next Y-2.13 Insider Trans- Shs Float35.29M Perf Month6.55%
Income-104.50M PEG- EPS next Q-0.60 Inst Own73.90% Short Float4.85% Perf Quarter-14.98%
Sales18.00M P/S9.74 EPS this Y5.10% Inst Trans-1.96% Short Ratio5.04 Perf Half Y48.78%
Book/sh3.39 P/B1.44 EPS next Y5.40% ROA-48.00% Target Price8.83 Perf Year25.77%
Cash/sh3.54 P/C1.38 EPS next 5Y- ROE-71.60% 52W Range1.75 - 7.34 Perf YTD6.32%
Dividend- P/FCF- EPS past 5Y-16.90% ROI-94.30% 52W High-33.51% Beta1.92
Dividend %- Quick Ratio6.70 Sales past 5Y-5.00% Gross Margin- 52W Low178.86% ATR0.41
Employees87 Current Ratio6.70 Sales Q/Q3.00% Oper. Margin- RSI (14)42.68 Volatility6.17% 7.93%
OptionableYes Debt/Eq0.00 EPS Q/Q51.50% Profit Margin- Rel Volume0.98 Prev Close5.52
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume339.56K Price4.88
Recom2.00 SMA20-10.68% SMA503.25% SMA2006.96% Volume333,955 Change-11.59%
Sep-22-20Upgrade Guggenheim Neutral → Buy $11
Jun-22-20Upgrade Wedbush Neutral → Outperform $5 → $9
Feb-28-20Downgrade JP Morgan Neutral → Underweight
Feb-18-20Downgrade Wedbush Outperform → Neutral
Nov-20-19Resumed Guggenheim Neutral
Oct-01-19Downgrade Guggenheim Buy → Neutral
Jun-03-19Downgrade Wells Fargo Outperform → Market Perform
May-29-19Initiated ROTH Capital Neutral $10
Apr-12-19Resumed Guggenheim Buy $24
Sep-13-18Resumed Leerink Partners Outperform $24
Jun-28-18Initiated Raymond James Mkt Perform
Jun-15-18Initiated JP Morgan Neutral $19
May-18-18Initiated Wedbush Neutral
Nov-06-17Reiterated RBC Capital Mkts Outperform $41 → $50
Sep-15-17Initiated RBC Capital Mkts Outperform $41
Mar-02-17Initiated Instinet Buy $94
Oct-25-16Initiated Citigroup Buy
Jan-21-16Initiated Credit Suisse Outperform
Dec-04-15Resumed Wells Fargo Outperform
Oct-19-15Reiterated Oppenheimer Outperform $45 → $48
Oct-28-20 12:32PM  
Oct-27-20 10:29PM  
Oct-13-20 02:47PM  
Oct-12-20 08:48AM  
Oct-09-20 09:50AM  
Sep-22-20 09:36AM  
Sep-09-20 06:30PM  
Aug-13-20 03:30PM  
Aug-10-20 12:56PM  
Aug-06-20 08:30PM  
Jul-30-20 12:33PM  
Jul-29-20 07:00PM  
Jun-26-20 09:17AM  
Jun-22-20 10:48AM  
Jun-11-20 07:53AM  
May-15-20 09:37AM  
May-10-20 09:55AM  
May-07-20 04:05PM  
Apr-30-20 04:05PM  
Apr-22-20 04:05PM  
Apr-14-20 09:00AM  
Apr-09-20 07:35AM  
Mar-20-20 03:32AM  
Mar-13-20 09:25AM  
Feb-27-20 05:45PM  
Feb-25-20 04:22PM  
Feb-20-20 12:31PM  
Feb-19-20 09:25AM  
Feb-18-20 09:25AM  
Feb-13-20 04:05PM  
Jan-10-20 09:28AM  
Dec-30-19 01:05PM  
Dec-27-19 02:26PM  
Dec-26-19 04:05PM  
Dec-20-19 01:54PM  
Dec-16-19 06:17PM  
Dec-10-19 11:14AM  
Nov-09-19 07:00AM  
Nov-08-19 01:02PM  
Nov-06-19 06:45PM  
Oct-30-19 10:33AM  
Oct-24-19 04:01PM  
Oct-11-19 04:04PM  
Oct-10-19 09:57PM  
Oct-02-19 07:30AM  
Sep-30-19 03:01AM  
Sep-20-19 09:59AM  
Sep-19-19 04:05PM  
Aug-22-19 07:45PM  
Aug-15-19 10:16PM  
Aug-07-19 06:25PM  
Aug-01-19 03:06PM  
Jun-25-19 11:56AM  
Jun-24-19 04:05PM  
Jun-18-19 08:50AM  
Jun-09-19 03:05PM  
Jun-01-19 09:01AM  
May-24-19 04:01PM  
May-17-19 12:45PM  
May-15-19 06:39PM  
May-09-19 11:23AM  
May-08-19 06:45PM  
May-01-19 10:33AM  
Apr-30-19 09:04AM  
Apr-17-19 07:56PM  
Mar-25-19 09:19AM  
Mar-20-19 02:09PM  
Mar-19-19 09:28AM  
Mar-11-19 06:00AM  
Mar-05-19 06:05PM  
Feb-26-19 09:47PM  
Feb-20-19 08:05PM  
Feb-07-19 04:05PM  
Feb-04-19 05:05PM  
Jan-30-19 11:45PM  
Jan-28-19 09:37AM  
Jan-24-19 03:13AM  
Jan-17-19 02:05PM  
Jan-16-19 07:40AM  
Jan-15-19 05:08PM  
Jan-14-19 06:41PM  
Jan-13-19 03:50PM  
Dec-12-18 04:05PM  
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/IL10% OwnerOct 06Buy5.04345,2411,738,2884,336,875Oct 08 05:27 PM
BVF PARTNERS L P/IL10% OwnerSep 22Buy3.8032122541,116Sep 24 07:49 PM
BVF PARTNERS L P/IL10% OwnerMay 14Buy4.10293,5871,203,7074,179,093May 18 08:02 PM
BVF PARTNERS L P/IL10% OwnerDec 20Buy4.05515,0202,085,8313,929,792Dec 26 05:59 PM
BVF PARTNERS L P/IL10% OwnerDec 09Buy4.02135,000542,3633,648,474Dec 11 06:13 PM
BERGER FRANKLIN MDirectorDec 03Sale4.0047,890191,5605,000Dec 04 06:28 PM
BERGER FRANKLIN MDirectorDec 02Sale3.9232,090125,79352,890Dec 04 06:28 PM
BVF PARTNERS L P/IL10% OwnerNov 22Buy3.401,120,0103,808,1463,534,600Nov 26 05:59 PM
BVF PARTNERS L P/IL10% OwnerNov 05Buy4.00968,1123,872,4482,958,503Nov 07 07:22 PM
BVF PARTNERS L P/IL10% OwnerOct 31Buy3.856,83326,3042,461,782Oct 31 06:24 PM
BVF PARTNERS L P/IL10% OwnerOct 30Buy3.8920,08178,1572,458,366Oct 31 06:24 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.